Research Article
BibTex RIS Cite

Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Year 2023, Volume: 27 Issue: 4, 1626 - 1637, 28.06.2025

Erhan Kilicoglu Ayşe Nur Hazar-yavuz , Gül Sinemcan Kabataş , Yusufhan Yazır , Levent Kabasakal

Abstract

Inflammatory bowel disease (IBD) is a complex disease with an incompletely understood multifactorial etiopathogenesis. The importance of intestinal microbiota in IBD and the role of probiotics in the treatment are being extensively investigated. This study evaluated the therapeutic effects of Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus reuteri, Saccharomyces boulardii and Bacillus clausii in trinitrobenzene sulfonic acid (TNBS)-induced colitis animal model. Rats were randomly grouped into 7: control, colitis, colitis+BB-12, colitis+L. reuteri, colitis+S. boulardii, colitis+B. clausii and colitis+methylprednisolone (positive control) treatment groups. Colitis was induced by the administration of intracolonically 80 mg/kg TNBS. Treatments continued for 7 days. Body weight, stool consistency, rectal bleeding, and disease activity index (DAI) scores were evaluated and recorded daily. Macroscopic and microscopic colonic damage were evaluated and scored in the last day of experiment. Levels of malondialdehyde (MDA) and glutathione (GSH) and activity of myeloperoxidase (MPO) in the colonic tissues were detected by ELISA. Our results showed that treatments with BB-12, L. reuteri, S. boulardii and B. clausii significantly improved on clinical symptoms and decreased macroscopic and microscopic colonic damage on experimental colitis in rats. In addition, L. reuteri and S. boulardii significantly increased GSH levels and decreased MDA levels and MPO activity. When we evaluate our findings, we think that supplements of these specific probiotics may have beneficial effects in the treatment of IBD.

Keywords

Probiotics inflammatory bowel disease experimental colitis trinitrobenzene sulfonic acid disease activity index

References

  • GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. https://doi.org/10.1016/S2468-1253(19)30333-4
  • Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014 Jan 7;20(1):91-9. https://doi.org/10.3748/wjg.v20.i1.91
  • Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021 Nov 30;2:100070. https://doi.org/10.1016/j.crphar.2021.100070
  • Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017 Apr 29;389(10080):1741-1755. https://doi.org/10.1016/S0140-6736(16)31711-1
  • Du L, Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am. 2020 Dec;49(4):643-654. https://doi.org/10.1016/j.gtc.2020.07.005
  • Molnar T, Annaházi A. Pathogenesis of Ulcerative Colitis and Crohn’s Disease: Similarities, Differences and a Lot of Things We Do Not Know Yet. J Clin Cell Immunol. 2014;5:253. https://doi.org/10.4172/2155-9899.1000253
  • Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015 Nov;169(11):1053-60. https://doi.org/10.1001/jamapediatrics.2015.1982
  • Younis N, Zarif R, Mahfouz R. Inflammatory bowel disease: between genetics and microbiota. Mol Biol Rep. 2020 Apr;47(4):3053-3063. https://doi.org/10.1007/s11033-020-05318-5
  • Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–514. https://doi.org/10.1038/nrgastro.2014.66
  • Yeşilyurt N, Yılmaz B, Ağagündüz D, Capasso R. Involvement of Probiotics and Postbiotics in the Immune System Modulation. Biologics. 2021;1:89-110. https://doi.org/10.3390/biologics1020006
  • Kim SK, Guevarra RB, Kim YT, et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J Microbiol Biotechnol. 2019 Sep 28;29(9):1335-1340. https://doi.org/10.4014/jmb.1906.06064
  • Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. https://doi.org/10.1016/S0140-6736(17)32448-0
  • Zhao M, Gönczi L, Lakatos PL, Burisch J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J Crohns Colitis. 2021 Sep 25;15(9):1573-1587. https://doi.org/10.1093/ecco-jcc/jjab029
  • Tian T, Wang Z, Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev. 2017;2017:4535194. https://doi.org/10.1155/2017/4535194
  • Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne). 2021 Dec 20;8:765474. https://doi.org/10.3389/fmed.2021.765474
  • McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018 May 7;5:124. https://doi.org/10.3389/fmed.2018.00124
  • Kilicoglu E. Prebiotics and Probiotics. In: Sener G, Goren ZM, Okuyan B, Yegen CB (Eds). Güncel Farmakoloji Fizyoloji Temelinde Hasta Odaklı Yaklaşım. Güneş Kitabevi, Ankara, 2022, pp. 894-897.
  • Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012 Apr 16;72(6):803-23. https://doi.org/10.2165/11632710-000000000-00000
  • Martyniak A, Medyńska-Przęczek A, Wędrychowicz A, Skoczeń S, Tomasik PJ. Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. Biomolecules. 2021 Dec 18;11(12):1903. https://doi.org/10.3390/biom11121903
  • Wang Y, Wu Y, Wang Y, et al. Antioxidant Properties of Probiotic Bacteria. Nutrients. 2017 May 19;9(5):521. https://doi.org/10.3390/nu9050521
  • Antoniou E, Margonis GA, Angelou A, et al. The TNBS-induced colitis animal model: An overview. Ann Med Surg (Lond). 2016 Aug 19;11:9-15. https://doi.org/10.1016/j.amsu.2016.07.019
  • Silva I, Solas J, Pinto R, Mateus V. Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease. Int J Mol Sci. 2022 Apr 25;23(9):4739. https://doi.org/10.3390/ijms23094739
  • Dodda D, Chhajed R, Mishra J, Padhy M. Targeting oxidative stress attenuates trinitrobenzene sulphonic acid induced inflammatory bowel disease like symptoms in rats: role of quercetin. Indian J Pharmacol. 2014 May-Jun;46(3):286-91. https://doi.org/10.4103/0253-7613.132160
  • Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp. 2012 Feb 1;(60):3678. https://doi.org/10.3791/3678
  • Javed NH, Alsahly MB, Khubchandani J. Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-Induced Colitis. Scientifica (Cairo). 2016;2016:9572596. https://doi.org/10.1155/2016/9572596
  • Satish Kumar CS, Kondal Reddy K, Boobalan G, et al. Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. Res Vet Sci. 2017 Feb;110:40-46. https://doi.org/10.1016/j.rvsc.2016.10.010
  • Utku OG, Karatay E, Ergul B, et al. Is the Probiotic Mixture Effective in the Treatment of TNBS-induced Experimental Colitis? JAREM. 2020;10(1):41-7. https://doi.org/10.4274/jarem.galenos.2019.2247
  • Chen LL, Wang XH, Cui Y, et al. Therapeutic effects of four strains of probiotics on experimental colitis in mice. World J Gastroenterol. 2009 Jan 21;15(3):321-7. https://doi.org/10.3748/wjg.15.321
  • Jakubczyk D, Leszczyńska K, Górska S. The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review. Nutrients. 2020 Jul 2;12(7):1973. https://doi.org/10.3390/nu12071973
  • Wilkins T, Sequoia J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am Fam Physician. 2017 Aug 1;96(3):170-178. PMID: 28762696
  • Sha S, Xu B, Kong X, et al. Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis. Inflamm Res. 2014 Oct;63(10):873-83. https://doi.org/10.1007/s00011-014-0761-1
  • Soyturk M, Saygili SM, Baskin H, et al. Effectiveness of Saccharomyces boulardii in a rat model of colitis. World J Gastroenterol. 2012 Nov 28;18(44):6452-60; discussion p. 6459. https://doi.org/10.3748/wjg.v18.i44.6452
  • Ackerman Z, Karmeli F, Cohen P, Rachmilewitz D. Experimental colitis in rats with portal hypertension and liver disease. Inflamm Bowel Dis. 2003 Jan;9(1):18-24. https://doi.org/10.1097/00054725-200301000-00003
There are 33 citations in total.

Details

Primary Language English
Subjects Medical Pharmacology
Journal Section Articles
Authors

Erhan Kilicoglu 0000-0002-3853-0408

Ayşe Nur Hazar-yavuz 0000-0003-0784-8779

Gül Sinemcan Kabataş 0000-0003-2168-1629

Yusufhan Yazır 0000-0002-8472-0261

Levent Kabasakal 0000-0002-5474-6436

Publication Date June 28, 2025
Published in Issue Year 2023 Volume: 27 Issue: 4

Cite

APA Kilicoglu, E., Hazar-yavuz, A. N., Kabataş, G. S., Yazır, Y., et al. (2025). Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of Research in Pharmacy, 27(4), 1626-1637.
AMA Kilicoglu E, Hazar-yavuz AN, Kabataş GS, Yazır Y, Kabasakal L. Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. J. Res. Pharm. July 2025;27(4):1626-1637.
Chicago Kilicoglu, Erhan, Ayşe Nur Hazar-yavuz, Gül Sinemcan Kabataş, Yusufhan Yazır, and Levent Kabasakal. “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”. Journal of Research in Pharmacy 27, no. 4 (July 2025): 1626-37.
EndNote Kilicoglu E, Hazar-yavuz AN, Kabataş GS, Yazır Y, Kabasakal L (July 1, 2025) Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of Research in Pharmacy 27 4 1626–1637.
IEEE E. Kilicoglu, A. N. Hazar-yavuz, G. S. Kabataş, Y. Yazır, and L. Kabasakal, “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”, J. Res. Pharm., vol. 27, no. 4, pp. 1626–1637, 2025.
ISNAD Kilicoglu, Erhan et al. “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”. Journal of Research in Pharmacy 27/4 (July 2025), 1626-1637.
JAMA Kilicoglu E, Hazar-yavuz AN, Kabataş GS, Yazır Y, Kabasakal L. Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. J. Res. Pharm. 2025;27:1626–1637.
MLA Kilicoglu, Erhan et al. “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”. Journal of Research in Pharmacy, vol. 27, no. 4, 2025, pp. 1626-37.
Vancouver Kilicoglu E, Hazar-yavuz AN, Kabataş GS, Yazır Y, Kabasakal L. Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. J. Res. Pharm. 2025;27(4):1626-37.